Full Press Release Details
Technologies' "Artificial Lung" to Acquire a Digital Edge:
Company Contracted GlobalLogic, a Hitachi Group Company, for
Advanced Digital Product Engineering
Israel / September 22, 2021/ -- Inspira Technologies OXY B.H.N. Ltd ("Inspira Technologies" or the "Company")
(Nasdaq: IINN, IINNW), a specialty medical device company engaged in the research, development, manufacturing, and marketing of
proprietary respiratory support technologies, announced
today that the the ART's device "brain" is to acquire an algorithm enhanced digital platform, for which the Company has contracted
GlobalLogic, a Hitachi Group Company ("GlobalLogic"), a world leader in digital product engineering.
"brain" of the ART device is an algorithm-enhanced control platform. A
unique feature of the ART's "brain" is the algorithm-based "hemo-protective patient's flow rate"- an
algorithm that is designed to manage the early rebalancing of the patient's oxygen saturation levels. In
addition, it includes a digital algorithm enhanced platform designed to activate and control proprietary technologies and data collected
from advanced sensors that measure oxygen saturation, blood temperature, haemoglobin, and haematocrit as well as pressure and flow of
Ben-Noon, Inspira's CEO, stated: "With concern over the rising morbidity associated with the COVID-19 pandemic, Inspira Technologies
is progressing towards the production phase of the ART device's "brain", an algorithm enhanced platform. The ART is
designed to provide oxygenation of blood and removal of carbon dioxide from the blood. With GlobalLogic, we are pleased to integrate
an advanced digital algorithm into our innovative control platform and to provide a more advanced digital experience for the medical
personnel who will use it.
Kolley, Group Vice President, Health Care and Life Sciences, GlobalLogic, stated: "We have all witnessed the wide-reaching impact
of COVID-19 and the stress it has created on healthcare resources. It's very gratifying to see industry leaders stepping forward
to solve these critical problems. We are thrilled to work with Inspira Technologies on this game-changing technology and looking forward
to the potential positive impact it will have on human lives."
Technologies selected GlobalLogic for its vast experience in working with regulated industries such as medical device and pharmaceutical
companies. GlobalLogic works with many of the world's leading medical
technology, healthcare, and life sciences organizations to create world-class digital patient
experiences, get products to market faster, uncover and capture new revenue streams, and transform healthcare through technology and
Technologies OXY B.H.N. Ltd.
Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective
early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory
patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are
awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet been
tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).
more information, please visit our corporate website:
(www.globallogic.com) is a leader in digital product engineering. We help brands across the globe design and
build innovative products, platforms, and digital experiences for the modern world. By integrating experience design,
complex engineering, and data expertise -- we help our clients imagine what's possible and accelerate their transition
into tomorrow's digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering
centers around the world, extending our deep expertise to customers in the healthcare and life sciences, communications, financial
services, automotive, technology, media and entertainment, manufacturing, and semiconductor industries. GlobalLogic is
a Hitachi Group Company.
Statement Disclaimer
press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company
is using forward-looking statements when it discusses that its ART has the potential to acquire a digital which is intended to minimize
the need for mechanical ventilation, and that the collaboration with GlobalLogic will have a potential positive impact on human lives.These
forward-looking statements and their implications are based on the current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the
Company's Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov.
Segal, Investor Relations, MS-IR LLC
Efraty, Public Relations & IR